MedCity News March 6, 2025
The future will see more pharma companies leveraging AI to improve diversity and inclusion, especially in trials that are diverse by design, as well as the odds of finding patients who fit an acceptable set of inclusion/exclusion criteria to accelerate clinical trial timelines.
Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the bench to the clinic and beyond.
According to a survey by the Tufts Center for the Study of Drug Development (Tufts CSDD), one-third of respondents report partial or full implementation of AI to support clinical trial planning, design, execution, and regulatory submission. As per the same survey, the...
Today's Sponsors
Today's Sponsor